America's Source for Battery- Grade Graphite NYSE American: WWR Q4 2025 Results Webcast March 2026 1 | westwaterresources.net | NYSE: American – WWR Cautionary Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "positioned to become," "strategically located," "growing EV market", "forecast," "expected," "wi ...

Financial Data and Key Metrics Changes - As of December 31, 2025, Cellectis reported cash equivalents, restricted cash, and fixed-term deposits amounting to $211 million, a decrease of $53 million from $264 million as of December 31, 2024, primarily due to cash payments and operational expenses [19][20] - The company managed its cash with discipline, focusing on the development of lasme-cel and eti-cel, and believes its current cash position is sufficient to fund operations into the second half of 2027 [18][19] Business Line Data and Key Metrics Changes - Lasme-cel achieved a 100% overall response rate in the target phase 2 population, with 80% of patients achieving minimal residual disease (MRD) negative status [5][12] - Eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in heavily pre-treated patients during phase 1 trials [8][16] Market Data and Key Metrics Changes - Cellectis is advancing its pivotal phase 2 trial for lasme-cel, with site openings in North America and Europe expected to continue into 2026 [7][12] - The company is also investigating eti-cel's potential impact with low-dose interleukin-2 support to enhance CAR-T efficacy without increasing toxicity [8][16] Company Strategy and Development Direction - Cellectis aims to transform into a late-stage development organization, with 2026 expected to be a year of significant milestones and data readouts [10][17] - The company is focused on delivering clinical results for patients with no therapeutic solutions, emphasizing the importance of its allogeneic CAR-T approach [4][5] Management's Comments on Operating Environment and Future Outlook - Management highlighted the challenges faced by biotechnology companies in recent years but emphasized Cellectis's commitment to advancing its clinical programs [4][5] - The management expressed confidence in the potential of lasme-cel and eti-cel to provide significant therapeutic options for patients with difficult-to-treat cancers [6][8] Other Important Information - Cellectis's gene editing platform is becoming the backbone of a broader allogeneic CAR-T ecosystem, with partnerships with Servier and Iovance advancing their respective programs [9][10] - The company anticipates presenting full phase 1 data for eti-cel later this year and expects to submit a Biologics License Application (BLA) for lasme-cel in the second half of 2028 [17][19] Q&A Session Summary Question: Update on lasme-cel and BALLI-01 enrollment - Management confirmed that recruitment is on track and expects to complete data analysis by the end of the year for the first 40 patients [23][24] Question: Expectations for dose optimization in the pivotal study - Management indicated that they have a strong analysis plan to differentiate between the two alemtuzumab dose levels, focusing on efficacy and safety [25][26] Question: Details on Servier arbitration and its impact - Management clarified that the arbitration ruling allows Cellectis to develop UCART19 independently while remaining eligible for milestones related to cema-cel [28][30] Question: Safety of CD52 preconditioning - Management emphasized the importance of alemtuzumab in optimizing lymphodepletion and achieving better outcomes [32][33] Question: Update on esiCell and patient follow-up - Management provided a top-line update on esiCell, indicating strong complete remission rates and plans for further data on IL-2 cohorts [35][36] Question: Competitive landscape regarding CD19 therapies - Management noted that their focus is on CD22, differentiating their product from others targeting CD19, and emphasized the need for alternative therapies for patients [41][42] Question: Expectations for EHA updates - Management indicated that they will present an updated dataset at EHA, including additional patients and insights on optimal lymphodepletion [50][52] Question: Outpatient setting for lymphodepletion procedures - Management stated that regulatory requirements currently necessitate inpatient delivery, but there is potential for outpatient use in the future [56][57] Question: AstraZeneca partnership updates - Management expressed satisfaction with the collaboration and indicated that updates will be provided when appropriate [58][60]

INVESTOR DAY M A R C H 2 0 , 2 0 2 6 THE CORE 2030 STRATEGY Powering Progress at the Heart of Motion & Control N Y S E : H L I O AGENDA & BACKGROUND TANIA ALMOND Vice President, Investor Relations & Corporate Communication 2 SAFE HARBOR This presentation and oral statements made by management in connection herewith contain "forward‐looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward‐looking statements involve risks and uncertainties, and actual results may d ...

FY 2025 FINANCIAL RESULTS Audited figures March 20, 2026 1 2 3 What we did last month TOM FORD FASHION Fall Winter 2026 What we did in the last month THOM BROWNE thom browne x ASICS sportstyle 4 What we did in the last month 5 ZEGNA MEMORIE What we did in the last month 6 ZEGNA Villa Zegna FY 2025 RESULTS - KEY HIGHLIGHTS1,2 €1,917m -1.5% Year-on-Year (YoY) +1.1% organic growth3 Consolidated Revenues Profit and Net Cash Surplus €109m profit (5.7% margin) vs. €91 and 4.7% margin in FY 2024 €52m Cash surplus ...

INVESTOR OVERVIEW MARCH 2026 Forward-Looking Statements Some of the statements contained in this presentation may constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, projections, plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as ''may,'' '' ...

Clinical-Stage Oncology Company Advancing New Targeted Cancer Therapies A transformative transaction combining proven drug development expertise with a first-in-class therapeutic candidate targeting solid tumours March 2026 Disclaimer NOT FOR RELEASE, PUBLICATIONOR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, OR THE REPUBLIC OF SOUTH AFRICAOR ANY OTHER JURISDICTIONIN WHICH IT WOULD BE UNLAWFUL TO DOSO. For the purposes of this document, t ...

FUCHS GROUP Investor Presentation March 2026 Agenda | Megatrends 04 | Business Model | FUCHS – a profitable growth story 01 05 | Financial Results FY 2025 | Appendix 02 06 03 | Review FUCHS2025 E-Mobility Sustainability Digitalization 01 Business Model FUCHS AT A GLANCE | | | No. 1 | The Fuchs family holds | | --- | --- | --- | --- | | | | among the independent | 59% of | | | | suppliers of lubricants | ordinary shares | | 3 Established | | | | | generations ago as a | | €3.6 bn | | | family-owned business ...

Financial Data and Key Metrics Changes - In Q4, the company returned to positive net sales growth with a reported increase of 2.2% and approximately 1% on a constant currency basis [3][4] - Gross margin improved to 60.3%, a 10-basis point increase from the previous year, attributed to regional mix and effective tariff mitigations [4][31] - Adjusted EBITDA margin was 20.3% for Q4, maintaining a strong performance while investing in new store openings [32] Business Line Data and Key Metrics Changes - The direct-to-consumer (D2C) business saw strong growth, with D2C e-commerce up 12% and D2C blended sales up 5.2% [12] - Non-travel categories grew by 6.7% year-over-year, now representing 37.6% of total sales [13] - Travel sales experienced a slight decrease of 2.2% compared to the previous year, but showed sequential improvement from -5.3% [14] Market Data and Key Metrics Changes - Asia showed significant improvement with a 5.1% growth on a constant currency basis in Q4, driven by strong performances in China, Korea, India, and Japan [8][9] - North America remained challenging but showed sequential improvements, particularly in the U.S. and Canada [9] - Europe experienced steady growth at 1% for both quarters, with D2C retail up 4.4% and e-commerce up over 9% [9] Company Strategy and Development Direction - The company plans to focus on amplifying brand awareness, enhancing digital capabilities, and expanding into lifestyle bags and accessories [15][18] - Marketing spend is expected to increase to 6.5% of net sales in 2026 to support strategic priorities [40] - The company is preparing for a dual listing in the U.S. to enhance shareholder value [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by travel demand and strategic execution [38] - The ongoing conflict in the Middle East is expected to impact Q1 sales, with a forecast of flat growth on a constant currency basis [39] - The company remains focused on maintaining strong gross margins despite external uncertainties [39] Other Important Information - The company generated strong adjusted free cash flow of $246 million for the year, with a healthy balance sheet showing a net debt position of approximately $1.1 billion [35] - The company received recognition for sustainability efforts, ranking 74th in Time's World's Best Companies in Sustainable Growth for 2025 and 2026 [25] Q&A Session Summary Question: Performance by market and resilience trends - Management noted sequential improvement across all business areas, with specific growth in Japan, Korea, and China, while the Middle East faced challenges [47][48] Question: Cost pressures due to Middle East conflicts - Management acknowledged potential short-term impacts on shipping and raw material costs but emphasized their ability to manage inventory and maintain margins [49][50] Question: Margin expectations for Q1 and store expansion plans - Management indicated that gross margins are expected to remain strong, with store expansions focused on Asia and Europe, particularly for TUMI [55][56] Question: Revenue trends in North America and wholesale customer sentiment - Management observed that wholesale customers in North America are buying cautiously, with a mixed trend for TUMI and improving performance for other brands [62]

Financial Data and Key Metrics Changes - In Q4, the company returned to positive net sales growth with a reported increase of 2.2% and approximately 1% on a constant currency basis [3][4] - Gross margin improved to 60.3%, a 10 basis point increase from the previous year, attributed to regional mix and brand strength [4][31] - Adjusted EBITDA margin was 20.3% for Q4, maintaining a strong performance while investing in new store openings [32][34] - Adjusted net income for Q4 was $106 million, down from $116 million in the prior year [32] Business Line Data and Key Metrics Changes - The direct-to-consumer (D2C) business saw strong growth, with D2C e-commerce up 12% and D2C blended sales up 5.2% [12] - Non-travel categories grew by 6.7% year-over-year, now representing 37.6% of total sales [13] - Travel category sales decreased by 2.2% compared to the prior year but showed sequential improvement from a negative 5.3% [14] Market Data and Key Metrics Changes - Asia experienced a significant recovery with 5.1% growth on a constant currency basis in Q4, driven by strong performance in China, Korea, India, and Japan [8][9] - North America showed sequential improvement, although still facing challenges from prior year comparisons [9] - Europe maintained steady growth at 1% for both quarters, with strong D2C performance particularly in Q4 [9] Company Strategy and Development Direction - The company plans to focus on four strategic pillars: amplifying brand awareness, winning in digital, seizing opportunities in lifestyle bags, and enhancing product development [15][17] - Marketing spend is expected to increase to 6.5% of net sales in 2026 to support these strategic priorities [18][40] - The company is preparing for a dual listing in the U.S. to enhance shareholder value [29][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by travel demand and strategic execution [38] - The ongoing conflict in the Middle East is expected to impact Q1 sales, with a forecast of flat growth on a constant currency basis [38][39] - The company aims to maintain strong gross margins despite uncertainties in the market [39] Other Important Information - The company generated strong adjusted free cash flow of $246 million for the year, with $170 million in Q4 [35] - The balance sheet remains healthy with a net debt position of approximately $1.1 billion [35] - The company received recognition for sustainability efforts, ranking 74th in Time's World's Best Companies in Sustainable Growth [25] Q&A Session Summary Question: Performance by market and resilience trends - Management noted sequential improvement across all business areas, with specific impacts in the Middle East and resilience in Japan, Korea, and China [47][48] Question: Cost pressures from Middle East conflicts - Management acknowledged early signs of cost impacts, particularly in shipping and raw materials, but emphasized their ability to manage margins effectively [49][50] Question: Margin expectations for Q1 and store expansion plans - Margins are expected to remain stable in Q1, with store expansions focused on Asia and Europe, particularly for TUMI [54][56] Question: Revenue trends in North America and wholesale customer sentiment - North America is experiencing a mixed trend, with sell-through strong but wholesale customers remaining cautious [62] Question: Shareholder return expectations post dual listing - The company plans to maintain a dividend payout ratio of around 45% of adjusted net income and will evaluate share buybacks after the dual listing [63][64]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a net sales increase of 2.2% on a reported basis and approximately 1% on a constant currency basis, marking a return to positive growth [3][4] - Gross margin improved to 60.3%, a 10 basis point increase from the previous year, attributed to regional mix and effective tariff mitigation [4][30] - Adjusted EBITDA margin for Q4 was 20.3%, maintaining strong performance while investing in new store openings [31] Business Line Data and Key Metrics Changes - The direct-to-consumer (D2C) business saw significant growth, with D2C e-commerce up 12% and D2C blended sales up 5.2% [11] - The non-travel category grew by 6.7% year-over-year, now representing 37.6% of total sales [12] - Travel sales experienced a slight decrease of 2.2% compared to the previous year, but showed sequential improvement from a decline of 5.3% [13] Market Data and Key Metrics Changes - The Asia region showed a strong recovery with 5.1% growth on a constant currency basis in Q4, driven by improvements in China, Korea, India, and Japan [7][8] - North America experienced sequential improvements, although still facing challenges from prior year comparisons [8] - Europe maintained steady growth at 1% for both quarters, with strong D2C performance particularly in Q4 [8] Company Strategy and Development Direction - The company plans to focus on four strategic pillars: amplifying brand awareness, winning in digital, seizing opportunities in lifestyle bags, and enhancing product development [14][15] - Increased marketing spend is planned, targeting 6.5% of net sales in 2026 to support brand awareness and long-term growth [16][40] - The company is preparing for a potential dual listing in the U.S. to enhance shareholder value [28][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by travel demand and strategic execution, despite uncertainties from geopolitical conflicts [38][40] - The company anticipates Q1 2026 net sales to be flat on a constant currency basis due to the impact of the Middle East conflict [38] - Management highlighted the importance of maintaining strong gross margins and effective supplier relationships to navigate cost pressures [30][49] Other Important Information - The company generated strong adjusted free cash flow of $246 million for the year, with a healthy balance sheet showing a net debt position of approximately $1.1 billion [35] - The company received recognition for sustainability efforts, ranking 74th in Time's World's Best Companies in Sustainable Growth for 2025 and 2026 [23][24] Q&A Session Summary Question: Performance by market and resilience trends - Management noted sequential improvement across all business areas, with specific impacts in the Middle East and resilience in Japan, Korea, and China [47][48] Question: Cost pressures from Middle East conflicts - Management acknowledged early signs of cost impacts, particularly in shipping and raw materials, but emphasized their ability to manage margins effectively [49][50] Question: Margin expectations for Q1 and store expansion plans - Margins are expected to remain stable in Q1, with store expansions focused on Asia and Europe, particularly for TUMI [54][56] Question: Revenue trends in North America and wholesale customer sentiment - North America showed improving trends, although wholesale customers remain cautious in their purchasing [60][62] Question: Shareholder return expectations post dual listing - The company plans to maintain a dividend payout ratio of around 45% of adjusted net income and will evaluate share buybacks after the dual listing [63][64]